Amid drug shortages and recalls, at least 3 sellers of a widely used blood-pressure medication, valsartan, have raised prices since a series of safety-related recalls of the drug by other manufacturers; the FDA is attempting to conserve dwindling resources during the government shutdown by prioritizing drug applications; researchers are looking into a possible link between prescription opioids and a birth defect called gastroschisis.
Amid drug shortages and recalls, at least 3 sellers of a widely used blood-pressure medication, valsartan, have raised prices since a series of safety-related recalls of the drug by other manufacturers, The Wall Street Journal reported. In addition, of the nearly 120 drugs listed by the FDA as currently or recently in shortage, about one-third had price increases after the shortages started, according to the paper’s review of pricing data provided by RELX Group’s Elsevier health-information unit.The FDA is attempting to conserve dwindling resources during the government shutdown by prioritizing drug applications, The Washington Post reported. Commissioner Scott Gottlieb, MD, told the paper that the measures will only help preserve funds for a few weeks, and not months, if the shutdown is protracted. The 2018 fees are expected to run out about February 8, and the agency isn’t allowed to collect the 2019 fees during the shutdown, although it can shift funds from other activities.Researchers are looking into a possible link between prescription opioids and a birth defect called gastroschisis, the Associated Press reported. The condition causes an infant to be born with its intestines outside the stomach due to a hole in the abdominal wall. Most are repaired through surgery. Roughly 1800 such cases happen annually, but the number has been rising and officials don't know why.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More